Cannabis produces well over a hundred cannabinoids. THC and CBD get the attention because they are present in the largest amounts and have been studied the most. The rest are lumped together as minor cannabinoids, and they are now sold at a premium on claims that rarely have trials behind them.
The chemistry is worth understanding, because it explains both why these compounds are scarce and why some of the marketing is backwards.
CBG Is the Parent, Not a Sibling
Cannabigerol deserves its "mother cannabinoid" nickname, though the accurate version is slightly different. The plant makes CBGA, cannabigerolic acid, and enzymes convert CBGA into THCA, CBDA or CBCA. Whatever CBGA is left over decarboxylates into CBG.
That is why CBG content is usually below one percent in mature flower. The plant spends its CBGA making other things. High-CBG products come from cultivars bred to leave CBGA unconverted, or from harvesting early.
Proposed effects include antibacterial activity, effects on intraocular pressure, and appetite stimulation, largely from laboratory and animal work. CBG is non-intoxicating. Controlled human trials are scarce, so treat specific therapeutic claims as preliminary.
CBN Is Aged THC
Cannabinol is the one most commonly misrepresented. CBN is not a compound the plant produces in quantity. It forms when THC oxidises through exposure to air, light and time. Old cannabis has more CBN because its THC has degraded.
That origin makes the dominant marketing claim awkward. CBN is sold as the sleep cannabinoid, and the belief traces to the observation that old cannabis felt sedating. Old cannabis has also lost potency and terpenes, so attributing the sedation specifically to CBN was always an inference rather than a finding.
Controlled human data on CBN as a sleep aid is very limited. Products advertising it as a dedicated sleep molecule are ahead of the evidence.
CBC Is Understudied
Cannabichromene is often the third most abundant cannabinoid in some cultivars and among the least researched. It is non-intoxicating, appears not to bind CB1 strongly, and has shown activity at TRP channels involved in pain and inflammation signalling in preclinical work. Anti-inflammatory and neurogenesis-related effects have been proposed.
There is little human data. CBC is a legitimate research target and a weak basis for a product claim.
THCV and the Weight Loss Story
Tetrahydrocannabivarin has a shorter side chain than THC and behaves differently depending on dose. At low doses it appears to act as a CB1 antagonist, and at higher doses more like an agonist. The appetite-suppressant reputation comes from the antagonist behaviour.
It is sometimes marketed as diet weed. Human evidence is limited, doses in products are often low, and the dose-dependent flip means the effect is not a simple property of the molecule.
Delta-8 Is a Different Category
Delta-8 THC gets grouped with minor cannabinoids, and it belongs in its own bucket. It occurs naturally in trace amounts, so commercial delta-8 is chemically converted from hemp-derived CBD using acids and catalysts.
Two consequences follow. It is intoxicating, roughly comparable to but generally reported as milder than delta-9 THC. And because it is manufactured through a conversion, residual reagents and unintended by-products are a genuine quality concern. It is frequently sold in places where cannabis is prohibited, often outside the testing rules that regulated cannabis faces.
How to Read Minor Cannabinoid Products
Bottom Line
CBG is the precursor the plant converts into everything else, which is why it is scarce. CBN is what THC becomes as it ages, which undercuts its sleep branding. CBC and THCV are genuinely interesting and barely studied in humans. Delta-8 is a manufactured intoxicant that needs testing scrutiny more than the others.
Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before making any health-related decisions.